» Articles » PMID: 35313737

Bone Regeneration and Angiogenesis by Co-transplantation of Angiotensin II-Pretreated Mesenchymal Stem Cells and Endothelial Cells in Early Steroid-Induced Osteonecrosis of the Femoral Head

Overview
Journal Cell Transplant
Date 2022 Mar 22
PMID 35313737
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) have been shown to exert a positive impact on osteonecrosis of the femoral head (ONFH) in preclinical experiments and clinical trials. After the femoral head suffers avascular necrosis, the transplanted MSCs undergo a great deal of stress-induced apoptosis and senescence in this microenvironment. So, survival and differentiation of MSCs in osteonecrotic areas are especially important in ONFH. Although MSCs and endothelial cells (ECs) co-culture enhancing proliferation and osteogenic differentiation of MSCs and form more mature vasculature , it remains unknown whether the co-culture cells are able to repair ONFH. In this study, we explored the roles and mechanisms of co-transplantation of angiotensin II (Ang II)-MSCs and ECs in repairing early ONFH. , when MSCs and ECs were co-cultured in a ratio of 5:1, both types of cells managed to proliferate and induce both osteogenesis and angiogenesis. Then, we established a rabbit model of steroid-induced ONFH and co-transplantation of Ang II-MSCs and ECs through the tunnel of core decompression. Four weeks later, histological and Western blot analyses revealed that ONFH treated with Ang II-MSCs and ECs may promote ossification and revascularization by increasing the expression of collagen type I, runt-related transcription factor 2, osteocalcin, and vascular endothelial growth factor in the femoral head. Our data suggest that co-transplantation of Ang II-MSCs and ECs was able to rescue the early steroid-induced ONFH via promoting osteogenesis and angiogenesis, which may be regarded as a novel therapy for the treatment of ONFH in a clinical setting.

Citing Articles

Bioengineering strategies targeting angiogenesis: Innovative solutions for osteonecrosis of the femoral head.

Zhu W, Xu Z, Zhou D, Xu J, He Y, Li Z J Tissue Eng. 2025; 16:20417314241310541.

PMID: 39866964 PMC: 11760140. DOI: 10.1177/20417314241310541.


Angiogenesis of Avascular Necrosis of the Femoral Head: A Classic Treatment Strategy.

Wang P, Shao W, Wang Y, Wang B, Lv X, Feng Y Biomedicines. 2024; 12(11).

PMID: 39595143 PMC: 11591661. DOI: 10.3390/biomedicines12112577.


Co-culture of vascular endothelial cells enhances corticosterone production in steroid hormone-producing cells generated from adipose-derived mesenchymal stromal cells.

Niimi T, Tanaka T, Aoyagi C, Onda Y, Nagamitsu S, Kodama S Sci Rep. 2024; 14(1):18804.

PMID: 39138321 PMC: 11322653. DOI: 10.1038/s41598-024-69878-3.

References
1.
Li R, Lin Q, Liang X, Liu G, Tang H, Wang Y . Stem cell therapy for treating osteonecrosis of the femoral head: From clinical applications to related basic research. Stem Cell Res Ther. 2018; 9(1):291. PMC: 6202807. DOI: 10.1186/s13287-018-1018-7. View

2.
Xie Y, Hu J, Shi Z . MiR-181d promotes steroid-induced osteonecrosis of the femoral head by targeting SMAD3 to inhibit osteogenic differentiation of hBMSCs. Eur Rev Med Pharmacol Sci. 2018; 22(13):4053-4062. DOI: 10.26355/eurrev_201807_15393. View

3.
Gebru Y, Diao T, Pan H, Mukwaya E, Zhang Y . Potential of RAS inhibition to improve metabolic bone disorders. Biomed Res Int. 2013; 2013:932691. PMC: 3736485. DOI: 10.1155/2013/932691. View

4.
Kniazeva E, Kachgal S, Putnam A . Effects of extracellular matrix density and mesenchymal stem cells on neovascularization in vivo. Tissue Eng Part A. 2010; 17(7-8):905-14. PMC: 3063702. DOI: 10.1089/ten.TEA.2010.0275. View

5.
Volkmer E, Kallukalam B, Maertz J, Otto S, Drosse I, Polzer H . Hypoxic preconditioning of human mesenchymal stem cells overcomes hypoxia-induced inhibition of osteogenic differentiation. Tissue Eng Part A. 2009; 16(1):153-64. DOI: 10.1089/ten.TEA.2009.0021. View